Thomas Weisel Partners Group
Discovery Laboratories, Inc. (Nasdaq: DSCO) 56.7% LOWER; announced that, on April 17, 2009, it received a Complete Response letter from the U.S. FDA for Surfaxin for the prevention of Respiratory Distress Syndrome in premature infants. In its letter, the FDA focuses primarily on certain aspects of a Surfaxin biological activity test (BAT, a quality control stability and release test) that must be addressed before the Surfaxin application can be approved. Click here for the full report.
Sun Microsystems (Nasdaq: JAVA) 36% HIGHER; Oracle Corporation and JAVA have entered into a definitive agreement under which Oracle will acquire Sun common stock for $9.50 per share in cash. The transaction is valued at approximately $7.4 billion, or ...
